VANCOUVER, British Columbia, Nov. 01, 2018 (GLOBE NEWSWIRE) -- Auxly Cannabis Group Inc. (TSX.V: XLY) (OTCQX: CBWTF) ("Auxly" or the "Company") is pleased to announce that, further to the binding interim agreement announced on January 30th, 2018, the Company has received approval from the Secretaría Nacional para la Lucha contra el Lavado de Activos y el Financiamiento del Terrorismo (“SENACLAFT”), the government body overseeing foreign direct investments in Uruguay, for the Company’s acquisition of 80% of the issued and outstanding common shares (the “Transaction”) of Inverell S.A. (“Inverell”). The SENACLAFT approval represents the final Uruguayan regulatory milestone required for the closing of the Transaction (the “Closing”).
Inverell is a federally licensed Cannabis Operator based in Montevideo, Uruguay. Led by Dr. Raúl Urbina, Inverell is a large-scale outdoor producer of hemp plants for CBD extraction operating on an initial footprint of approximately 300 hectares. Inverell has recently commenced the planting of its feminized seeds on 150 hectares (approximately 16.1 million square feet) which it expects to complete by early December and harvest in mid-April of 2019.
Dr. Urbina completed his post-graduate studies in Molecular Biology at Princeton University and obtained his PhD in Agronics and Rural Development at the University of Almeria in Spain. Dr. Urbina was previously the Founder and Chief Executive Officer of Stevia One, where under his leadership, the company operated a 1,000 hectare cultivation operation in Peru. During this time, Dr. Urbina and his team developed superior strains of stevia which allowed Stevia One to achieve the highest yielding and lowest cost production of stevia in the world. Dr. Urbina has significant experience managing high-tech, large-scale agricultural projects with a strong focus on innovation having previously designed and managed the fully mechanised stevia plantation and high throughput extraction facility at Stevia One. Dr. Urbina’s track record of innovation has continued at Inverell where his breeding program has continually improved Inverell’s genetic library and his engineering team has recently completed the design of its proprietary, commercial scale, GMP compliant extraction facility using cold ethanol and chromatography purification.
Inverell provides the Company with a highly efficient, low-cost source of cannabinoids to address expanding global demand for cannabinoid-based products. The Company’s ownership of Inverell gives it a cornerstone asset through which to effectively exploit emerging international distribution channels, including through the Company's strategic partnership with ICC International Cannabis Corporation Inc. (CSE: WRLD) which provides the Company access to 16 markets through a network of 35,000 pharmacies. Importantly, the low cost, high purity CBD produced by Inverell gives the Company a long-term and stable supply of CBD to support the research, development and manufacturing of cannabis-derived products at Dosecann Inc., the Company's wholly-owned Licensed Processor facility located in Prince Edward Island, Canada.
The Company, through its wholly owned subsidiary Kolab Project, a Licenced Cultivator pursuant to the Cannabis Act, has also applied for a permit to import proprietary cannabis genetics from Inverell for use in the Company’s Canadian operations. The Company expects that, upon receipt of the permit to import, the Company will be able to import proprietary high CBD yielding genetics from Uruguay created through the breeding program at Inverell. The ability to import unique cannabis genetics will provide the Company with a competitive advantage for its Canadian operations through differentiated product offerings and efficiencies related to the Company’s cultivation and extraction efforts, particularly as the Company looks to ramp up its larger scale facilities and outdoor cultivation projects.
Hugo Alves, President of Auxly commented: “I couldn't be more excited to announce the closing of the Inverell transaction. Not only is Auxly acquiring an incredible project, but we are welcoming one of the world's foremost experts in large scale outdoor cultivation and the extraction of high value molecules from plants into the Auxly family. I speak for myself and everyone at Auxly in saying that we are thrilled and honored to have Raul and the whole Inverell team as our friends and business partners. Inverell is a hugely important asset for Auxly and our strategic vision. Through Inverell, Auxly is perfectly poised to play a leading role in the global CBD economy and establish itself as a leading manufacturer of value-added cannabinoid-based products for domestic and international markets. Our ability to exercise strict QA/QC controls along every point of the supply chain from cultivation to extraction to product manufacturing, all within jurisdictions where cannabis is federally legal, ensures that we will be able to meet the quality assurance and supply chain demands of increasingly sophisticated and institutional purchasers. I love it when a plan starts to come together and the acquisition of Inverell is a big piece of our plans so today is a very exciting day for our company."
Dr. Raúl Urbina, Founder and Chief Executive Officer of Inverell commented: “We could not be more pleased to have reached this historic milestone and to formally join the Auxly family. We are very excited to partner with a company that shares our core values and vision and one that will allow us to better deliver cannabis products under our 3 'P' philosophy: People, Planet, Profit.”
Under the terms of the Transaction, the shareholders of Inverell are entitled to receive aggregate consideration of approximately USD$15,000,000, to be paid as follows:
In connection with the Transaction, the Company has agreed to extend to Inverell up to an additional USD$5,000,000 by way of a secured loan repayable through cash flows generated by Inverell’s cultivation operations.
Closing of the Transaction remains subject to the approval of the TSX Venture Exchange.
ON BEHALF OF THE AUXLY BOARD
"Chuck Rifici" Chairman & CEO
About Auxly Cannabis Group Inc. (TSX.V: XLY) (OTCQX: CBWTF)
Auxly Cannabis Group is a collective of entrepreneurs with a passion for the cannabis industry past, present and future. Our mandate is to facilitate growth for our partners by providing them with financial support and sharing our collective industry experience. Our partners all have different visions, voices and brand values, and all share a common goal—to build a world-class industry based on ethics, diversity, quality and innovation.
Follow up on Twitter @AuxlyGroup
Media Enquiries (only):
For media enquiries or to set up an interview please contact:
Sarah Bain, VP External Affairs
Notice Regarding Forward Looking Information:
This news release contains certain "forward-looking information" within the meaning of applicable Canadian securities law. Forward-looking information is frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or information that certain events or conditions "may" or "will" occur. This information is only a prediction. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking information throughout this news release. Forward-looking information includes, but is not limited to: the satisfaction of all outstanding conditions to the completion of the Transaction, including receipt of the approval of the TSX Venture Exchange, Company's ability to obtain all requisite regulatory approvals for the production and export of cannabinoid products from Uruguay and/or import of such products to other federally legal jurisdictions, political changes in Canada, Uruguay and internationally, future legislative and regulatory developments involving cannabis in Canada, Uruguay and internationally, the Company’s ability to secure distribution channels in international jurisdictions, competition and other risks affecting the Company in particular and the cannabis industry generally.
A number of factors could cause actual results to differ materially from a conclusion, forecast or projection contained in the forward-looking information in this release including, but not limited to, whether: Inverell is able to maintain its cannabis operator license, the Company is able to successfully develop international distribution channels for cannabis products, Inverell is able to successfully cultivate and harvest outdoor hemp crops in Uruguay, Inverell can obtain all necessary governmental and regulatory permits and approvals for the Inverell extraction facility, and whether such permits and approvals can be obtained in a timely manner,, and general economic, financial market, regulatory and political conditions in which the Company operates will remain the same. Additional risk factors are disclosed in the revised annual information form of the Company for the financial year ended December 31, 2017 dated May 24, 2018.
New factors emerge from time to time, and it is not possible for management to predict all of those factors or to assess in advance the impact of each such factor on the Company's business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking information. The forward-looking information in this release is based on information currently available and what management believes are reasonable assumptions. Forward-looking information speaks only to such assumptions as of the date of this release. In addition, this release may contain forward-looking information attributed to third party industry sources, the accuracy of which has not been verified by the Company. The purpose of forward-looking information is to provide the reader with a description of management's expectations, and such forward-looking information may not be appropriate for any other purpose. Readers should not place undue reliance on forward-looking information contained in this release.
The forward-looking information contained in this release is expressly qualified by the foregoing cautionary statements and is made as of the date of this release. Except as may be required by applicable securities laws, the Company does not undertake any obligation to publicly update or revise any forward-looking information to reflect events or circumstances after the date of this release or to reflect the occurrence of unanticipated events, whether as a result of new information, future events or results, or otherwise.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.